Rapport Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 25.05 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 1.48B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Details
| Name | Rapport Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 84 |
| Founded | 2022 |
| Ipo Date | 2024-06-07 |
| Ceo | Abraham Ceesay |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 17.00 |
| Isin | US75383L1026 |
| Cusip | 75383L102 |
| Cik | 2012593 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Abraham N. Ceesay M.B.A. | Chief Executive Officer, President, Treasurer and Director |
| Dr. Steven M. Paul M.D. | Founder and Independent Chairman |
| Troy A. Ignelzi | Chief Financial Officer |
| Dr. Jeffrey Sevigny M.D. | Chief Medical Officer |
| Dr. David Bredt M.D., Ph.D. | Founder and Chief Scientific Officer |
| Cheryl Gault | Chief Operating Officer |
| Karina Chmielewski | Chief Information Officer and Head of Operations |
| Julie DiCarlo | Head of Communications and Investor Relations |
| Kathleen A. Wilkinson | Chief People Officer |
| Swamy Yeleswaram Ph.D. | Chief Development Officer |
Contact
| Address | 99 High Street, Suite 2100, Boston, Massachusetts 02110, United States |
| Phone | 857 321 8020 |
| Website | https://www.rapportrx.com |